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672 Metabolic Determinants of Metastatic Breast Cancer Simões et al. Neoplasia Vol. 17, No. 8, 2015suggest that themetabolic plasticity andadaptability aremore important to themetastatic breast cancer phenotype than rapid
cell proliferation alone, which could 1) provide a new biomarker for early detection of this phenotype, possibly at the time of
diagnosis, and 2) lead to new treatment strategies of metastatic breast cancer by targeting mitochondrial metabolism.
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Study Label
(13C)
Stage Experiment
Time (h)
Medium (mM) Oxygenation
Glucose Glutamine
A – A-1 0-1 25 6 Ox
Glc C1 A-2 1-6 25 2 Ox
Glc C1 A-3 6-32 25 6 Ox
B – B-1 0-1 25 6 Ox
Gln C3 B-2 1-6 25 6 Ox
Gln C3 B-3 6-11 25 6 H
Gln C3 B-4 11-16 0 6 Ox
Gln C3 B-5 16-21 0 6 H
– B-6 21-22 25 6 Ox
C – C-1 0-1 25 6 Ox
Glc C1 C-2 1-6 25 0 Ox
Glc C1 C-3 6-11 25 0 H
Glc C1 C-4 11-16 25 2 H
Glc C1 C-5 16-21 25 2 Ox
– C-6 21-22 25 6 Ox
Three different studies were carried out: A, B, and C. The first experimental hour of each
experiment was reserved for loading the sample into the MR spectrometer, MR probe tuning, and
matching, followed by sample shimming. Study A consisted of well-oxygenated cells perfused
continuously for 31 hours with 99% 1-13C-glucose–containing culture medium, initially with
2 mM glutamine (1-6 hours) and then with 6 mM glutamine (6-32 hours). In separate experiments,
cells were studied during four sequential 5-hour stress conditions in the presence of either 99%
3-13C-glutamine (study B) or 99% 1-13C-glucose (study C) in the culture/perfusion medium. In
study B, the experiment with 3-13C-Gln–labeled medium consisted of the four conditions/stages,
B2 to B5, evaluating the effects of the presence or absence of 25 mM glucose under well-oxygenated
or hypoxic conditions on glutaminemetabolism. In study C, the experiments with 99%1-13C-glucose–
labeled culture medium were carried out in four stages/environmental conditions: C-2 to C-5. The
perfusionmedia for stages C-4 andC-5 contained in addition to 2mMGln also a basal level of pyruvate
(1 mM). Abbreviations: Glc C1: 1-13C-glucose, Gln C3: 3-13C-glutamine, Ox: well-oxygenated
conditions, H: hypoxia.Introduction
Breast cancer is the most prevalent type of cancer among women in the
United States [1], and mortality is primarily caused by metastatic
disease. The complex mechanisms of breast cancer invasion and
metastasis [2] are intrinsically related to the malignant cell type [3], their
interaction with stromal cells [4,5], and changes in the tumor
microenvironment, related to poor perfusion, intermittent hypoxia,
transient nutrient deprivation, and acidity [6,7]. Cancer cells adapt to
dynamic stresses and proliferate by reprogramming their metabolism to
support synthesis of an expanding biomass [8,9]. Due to oncogene-
driven upregulation of key glycolytic enzymes [10], most cancer cells
exhibit aerobic glycolysis known as the Warburg effect [11]. This
metabolic phenotype has been studied by noninvasive techniques, such
as 18F-fluorodeoxyglucose positron emission tomography andmagnetic
resonance spectroscopy (MRS of 13C-labeled substrates) [12,13]. Due
to enhanced glycolysis, tumor cells synthesize high levels of lactate and
export H+, resulting in acidification of the microenvironment, which in
turn promotes invasion and dissemination [14,15]. Recent studies with
two isogenic murine breast cancer cell lines derived from the same
spontaneous breast tumor, 4T1 and 67NR [16], have shown differences
in lactate dehydrogenase (LDH) A expression during normoxia and
hypoxia [17]. However, other studies have highlighted the importance
of oxidative phosphorylation (OXPHOS) in tumorigenesis and
progression [18–20].
Because it is well recognized that tumor cells are often hypoxic and
nutritionally deprived in vivo[7], we have monitored in real time the
metabolic changes in live 4T1 and 67NR cells under conditions that
reflect these common, often transient, physiologic stresses. Our
hypothesis is that the metabolism of metastases-forming breast cancer
cells (4T1) is more adaptable to changes in the microenvironment
than the metabolism of isogenic, nonmetastatic cells (67NR), thus
providing 4T1 cells with a distinct advantage to grow, invade, and
proliferate under different conditions. Previous metabolic studies
using cell extracts have demonstrated marked differences in basal
glucose consumption, lactate production, and oxygen consumption
between these two cell lines grown in standard bidimensional tissue
culture conditions [17,21]. However, these studies have not
investigated the — potentially reversible — metabolic adaptations
of these cancer cells to in vivo tumor conditions, which include
changing microenvironmental stresses during tridimensional growth.
We used a magnetic resonance (MR)–compatible cell perfusion
system and time-course MRS of 13C isotopomers to investigate how
living cancer cells adapt their metabolism and growth to selective
supply/deprivation of glucose and glutamine under both aerobic and
hypoxic conditions. In contrast to standard 2D tissue culture studies,
the MR-compatible cell perfusion system allows high-density 3D
cancer cell growth and exposing cells dynamically and reversibly to
various tissue growth environments in a single sample, more similar to
the cellular microenvironment of small (b100 mm3), well-perfusedtumors. Moreover, compared with indirect metabolic measurements
based on dynamic extracellular pH and O2 changes (e.g. Seahorse XF
analyzer studies), the cell perfusion system allows measuring real-time
changes in intra- and extracellular metabolite levels and cellular
bioenergetic profiles by sequential multinuclear (13C, 31P) MRS.
Our assessment of the dynamic interplay between various environ-
mental stresses and tumor cell metabolic response clearly demon-
strates that 4T1 cells are more capable of adapting their metabolic
responses to changes in the microenvironment than 67NR cells. This
is largely accomplished in 4T1 cells by their greater plasticity and
ability to more effectively metabolize glucose through either glycolysis
or OXPHOS than 67NR cells, providing greater adaptability to a
changing tumor and metastatic microenvironment.
Materials and Methods
Cell Lines
The 67NR, 168FARN, 4T07, and 4T1 cell lines were initially derived
from a spontaneous breast tumor growing in a BALB/c mouse [16]. These
cell lines were kindly provided by Dr. Fred Miller (Karmanos Cancer
Institute, Detroit, MI) and grown in Dulbecco’s modified Eagle’s media
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penicillin, 100μg/ml of streptomycin, and 10% fetal calf serum, referred to
as DMEcompl. Cells were cultured in 5% CO2 / 95% air at 37 °C in a
humidified chamber, split every 2 to 3 days, and used up to passage 10.
Cell Perfusion Studies
For MR cell perfusion studies, 4T1 and 67NR cells were grown
to N70% confluence on microcarrier beads. The cell perfusion studies
were carried out on a 500-MHz AVANCE III Bruker MR system
equipped with a 10-mm BBO probe for 1H and 31P/13C acquisition
(Bruker BioSpin, Billerica, MA). Three different experimental studies
were performed for 4T1 and 67NR cell lines, as detailed in Table 1,
each consisting of three independent cell perfusion experiments per cell
line. During the experiments, the cells were continuously perfused with
media containing either 98% to 99% 1-13C-glucose (CLM-420-0;
Cambridge Isotope Labs, Billerica, MA) or 99% 3-13C-glutamine
(604941-SPEC; Sigma-Aldrich, St. Louis, MO), whereas 13C MR
spectra and 31P MR spectra were acquired repeatedly to assess
metabolism of the 13C-labeled nutrients and cellular energy status,
respectively. Tumor cell–conditioned medium (TCM) samples were
also collected at the end of the cell perfusion studies A (Table 1) and
stored at −20°C until high-resolution 1H-decoupled 13C MRS studies
were performed. Additional details about the cell perfusion system,MR
data acquisition, processing, and isotopomer analysis are provided in the
Supplementary Experimental Procedures.
Cell Culture Studies
The four isogenic cell lines (67NR, 168FARN, 4T07, and 4T1)
were seeded in 24-well cell culture microplates (5 × 104 cells/well).
When cells reached 70% confluence, DMEcompl was replaced with
different media containing 1-13C-glucose, as described for cell
perfusion studies A and C (Table 1: DMEcompl with 6 mM glutamine
and DMEcompl where 6 mM glutamine was replaced with 2 mM and
0 mM glutamine, respectively). Cells were grown for 5 hours either in
normoxia (20% oxygen) or in hypoxia (1% oxygen), at 37°C and
5% CO2, followed by collection of TCM2D, cell harvest, and cell
count for each sample. TCM2D samples were stored at −20°C.
High-resolution 13C MR spectra of TCM2D samples were acquired
to determine glucose consumption and lactate excretion in 2D
tissue culture and compare them with the results obtained
from TCM samples. Additional details regarding the MR data
acquisition, processing, and analysis are provided in the Supplementary
Experimental Procedures.Seahorse Bioscience XF96 Extracellular Flux
Analyzer Experiments
Both 4T1 and 67NR cells were seeded separately in the same
96-well plate at 1.0 × 104 and 2.0 ×104 cells per well, respectively.
After attachment and growth for 18 hours, the DMEcompl medium in
each well was changed to XF assay medium (102365-100; Seahorse
Bioscience, Billerica, MA) with the same glutamine and glucose
concentration as in DMEcompl and incubated for 1 hour in a CO2-free
atmosphere. The cells were then studied in an XF96 Analyzer
(Seahorse Bioscience, Billerica, MA), measuring the extracellular
acidification rate (ECAR; studied during the first 27 minutes) and the
oxygen consumption rate (OCR; 2-hour studies) in each well. During
the OCR studies, the specific respiratory chain inhibitors oligomycin
(inhibition of ATP synthase), Carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP; H+ ionophore, uncoupler), and antimycin Aplus rotenone (inhibition of complexes I and III, respectively,
disabling the electron transport completely in the respiratory chain)
(Sigma-Aldrich, St. Louis, MO) were sequentially injected into each
well at 30, 60, and 90 minutes, respectively [22]. The time course of
OCR values collected during data acquisition were normalized to the
total protein content in each well. The latter were determined at the end
of the experiment from the cell lysates (RIPA buffer; Thermo Scientific,
Rockford, IL) using the bicinchoninic acid protein assay (BCA kit;
Thermo Scientific Pierce, Rockford, IL). Measurements were summa-
rized by taking the geometric mean across wells for each cell line, at each
time point, and in each replicate of the experiment. The geometric
mean was used because of the skewed distribution of data across wells
within each experimental condition. In the specific case of ECAR, the
logarithmof ratios between paired 4T1 and 67NR results was calculated
based on data skewness and because a ratio of 1 translates into a log-ratio
of 0 when applying a one-sample t test across experimental replicates.
The same analysis was applied to the log-ratio of the geometric means
across the four time points and to the linear contrast, estimating the
slope of log-ratios versus time points. Finally, an additional experiment
was carried out to compare OCR measurements between all four
isogenic cell lines according to the protocol previously described. Results
were analyzed as above using the geometric means of the dynamic
readings in each microplate well (4T1, n = 21; 4T07, n = 22;
168FARN, n = 23; 67NR, n = 22).
Expression and Activity of Succinate Dehydrogenase (SDH)
In both 4T1 and 67NR cells, SDH protein expression was assessed
by Western blot of the SDH subunit A (SDH-A) using a monoclonal
antibody and a methodology analogous to our previous studies [17]. We
also used a polyclonal antibody to assess SDH-A expression by Western
blot in the four isogenic cell lines: Cells were exposed for 5 hours tomedia
with different concentrations of glucose (25 and 0mM) and glutamine (6,
2, and 0 mM) under normoxia and hypoxia, paralleling the media
conditions in MR cell perfusion studies as described in Table 1. The
Western blot protocols are provided in the Supplementary Experimental
Procedures. All results are averaged over three independent experiments.
The total SDH activity of 4T1 cells and 67NR was assessed using the
Complex II Enzyme Activity Microplate Assay Kit (ab109908; Abcam,
Cambridge, MA). The activity of SDHwas measured in parallel for fresh
lysates of 4T1 and 67NR cells, as described by the manufacturer.
Statistical Analyses
Statistical analyses were carried out with the t test (unless indicated
otherwise): unpaired when comparing 4T1 and 67NR data acquired
under the same experimental conditions ( indicates statistical
significance: P b .05) and paired when comparing the same cell
line in consecutive stages during the same study, as specified for each
experiment (# indicates statistical significance: P b .05). Results are
displayed as mean ± standard error (SEM). In graphs, error bars that
are smaller than the symbol size are not visible.
Results
Glycolytic Activity of 4T1 and 67NR Cells
We used an MR-compatible cell perfusion system to investigate the
differences in glucose metabolism between 4T1 and 67NR cells in the
presence of 6 mM and 2 mM glutamine (DMEcompl versus more
physiologic glutamine concentrations, respectively) (Study A, Table 1).
The bioenergetic profile and phospholipid metabolism were
measured dynamically during all cell perfusion studies by 31P
Figure 1. Basal glucose metabolism of live 4T1 and 67NR cells. MR cell perfusion studies (n = 3 for each cell line). (A) Representative
nuclear Overhauser effect–enhanced, 1D 1H-decoupled 13C MR spectra acquired from 4T1 (top) and 67NR (bottom) cells after 24-hour
perfusion with culture medium containing 1-13C-glucose (Glc), as detailed in Study A, Table 1. The regions from 80 to 50 ppm and 40 to
25 ppm are shown enlarged above the full spectra. All spectra are displayed with 10-Hz exponential line broadening. Signal assignments
of metabolites, with C1-6 depicting the position of the incorporated 13C label: alanine (Ala), dihydroxyacetone phosphate (DHAP), α- and
β-glucose (α-Glc and β-Glc, respectively), glutamate (Glu), glutamine (Gln), glutathione (GSH-Glu), glycerol (Gly), glycerol-3-phosphate
(G3P), lactate (Lac), methionine (Met), myo-inositol (myo-Ino), pyruvate (Pyr), succinate (Succ). (B) Average time-course changes for the
major peak areas, normalized to the initial β-NTP values (β-NTPinit, determined from
31PMRS; Figure S1). (C) Average 13C-labeling rates of
metabolites at different time intervals for the data shown in B.
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metabolism of 1-13C-glucose (Figure 1) was measured by 13C MRS.
Multiple 13C-labeled metabolites synthesized de novo by the tumor cells
from 1-13C-glucose were detected (Figure 1A). Their peak areas were
normalized to the initial number of cells (Figure 1,B andC) by referencing
to the corresponding β-NTPinit levels (Figure S1). Because glucose was
labeled only in the C1 position, 50% of the metabolic pool downstream of
fructose 1,6-diphosphate incorporated the 13C-label and was detected.
As shown in Figure 1, 4T1 cells demonstrated significantly higher
glycolytic activity than 67NR cells, independent of glutamine
concentrations in the perfusion medium (2 mM, 1-6 hours, P b .05;
and 6 mM, 6-32 hours, P b .05). During the initial 10 hours of
perfusion with 13C-labeled medium, the glucose consumption rate was
slightly higher in 4T1 cells than in 67NR cells and increased significantly
in 4T1 cells when changing themedium from2mMto 6mMglutamine
(after 6 hours) (Figure 1C). Under both experimental conditions, the
glycolytic-lactate synthesis rates were also approximately 1.5-fold higher
in 4T1 than in 67NR cells (1-6 hours, P b .05; 6-11 hours, P = .06),
closely matching the difference in doubling times between the two cell
lines. In standard tissue culture medium (25 mM glucose and 6 mM
glutamine), 4T1 cells have a doubling time of 13.6 ± 1.5 hours (n = 13,
mean ± SE) and proliferate significantly more rapidly than 67NR cells
[doubling time of 22.4 ± 1.8 hours (n = 16, mean ± SE)] (P b .05,
Mann-Whitney U test). Similar doubling times were measured when
the cells were grown under more physiological concentrations of glucose
(5 mM) [23]. The differences in proliferation were also reflected in the
bioenergetic and phosphomonoester profile of the two cell lines, with
β-NTP and PCho both increasing faster in the 4T1 cells than in 67NR
cells during cell growth in the perfusion system (Figure S1). The initial
rates (1-11 hours) of glucose consumption and total de novo extracellular
lactate (Lac) derived from 13C-labeled glucose (Figure S2; see
Supplementary Experimental Procedures) were similar to those obtained
in previous studies of glioma and EMT-6 cells [24,25].
The 13C-labeled pools of glycerol-3-phosphate [3-13C-G3P,
obtained by reduction of dihydroxyacetone phosphate
(1-13C-DHAP) and essential for membrane phospholipid synthesis]
and myo-inositol [4(6)-13C-myo-Ino, precursor of phosphatidyl
inositol phosphates] were also observed in 4T1 and 67NR cells
(Figure 1, B and C). Compared with 67NR cells, the higher levels of
3-13C-G3P and 4(6)-13C-myo-Ino in 4T1 cells also indicate their
higher glycolytic turnover and membrane biosynthesis requirements, in
both 2-mM and 6-mM glutamine medium, and relate to their invasive/
metastatic phenotypes, in agreement with Smirnova et al. [26].
The synthesis rate of glucose-derived alanine (3-13C-Ala, an
alternative end-product of glycolysis obtained by transamination of
3-13C-pyruvate with glutamate) was higher in 4T1 than in 67NR
cells. In response to increasing glutamine from 2 mM to 6 mM, the
synthesis rate of 3-13C-Ala increased 1.7-fold in 4T1 cells and
2.5-fold in 67NR cells (Figure 1C). In subsequent cell perfusion
experiments, under metabolic stress (Table 1, Study C: 0 and 2 mM
glutamine, under hypoxia and normoxia), both cell lines were
essentially unable to use glucose for alanine synthesis when fully
deprived of glutamine (Figure S3, 1-11 hours). These observations are
consistent with the central role of glutamine as a nitrogen donor for
biosynthesis of amino acids and nucleotides [27,28] and the greater
metabolic demands of the faster-growing, metastatic 4T1 cells.
Consistent with ongoing glycolytic activity and synthesis of
glucose-derived lactate in proliferating live cells, we observed in our
cell perfusion studies intra- and extracellular acidification during thefirst 18 hours, with pHi decreasing from 7.2 to 7.1 in both cell lines
(P b .05, paired t test) and pHe from 7.6 to 7.4 (P b .05 only for
67NR cells, paired t test) (Supplementary Experimental Procedures
and Figure S1B). The basal glycolytic activity of 4T1 and 67NR cells
was also measured for cells in 2D tissue culture by the ECAR
(Figure 2A). The ECAR measurements were significantly higher for
4T1 than for 67NR at each successive time point (P = .021, .023,
.041, and .05, respectively), and also for the geometric mean across
time points (P = .034). The mean of geometric ratios, between paired
4T1 and 67NR results, indicated 1.4-fold higher ECAR in 4T1
(Figure 2A), consistent with the ratios of the glucose-derived lactate
synthesis rates for 4T1 and 67NR obtained with the cell perfusion system
within the first 18 hours (1.7, 1.5, and 1.4), respectively (Figure 1C).
OXPHOS and Metastatic Potential
To investigate the role of OXPHOS in each cell line, we carried out
mitochondrial functional analyses under 2D growth conditions
(25 mM Glc, 6 mM Gln) by selective inhibition of different
respiratory complexes while measuring the effects on the cellular
OCR (Figure 2B). Consistent with the 31P MRS results on live,
perfused cells (Figure S1B), 4T1 cells showed a significantly higher
basal respiration rate (2.3-fold) and ATP production (2.2-fold) than
67NR cells (Figure 2C). When extending these measurements to two
additional cell lines from the same isogenic breast cancer family
(168FARN and 4T07), we noticed higher basal respiration and ATP
production with increasing metastatic ability: 4T1 (overt metastasis)
N 4T07 and 168FARN (micrometastasis) N 67NR (nonmetastatic)
(Figure 2, D and E).
Tricarboxylic Acid (TCA) cycle activity in 4T1 and 67NR cells
Both 4T1 and 67NR cells incorporated 1-13C-glucose into 4-
13C-glutamate (Figure 1, A and B) via pyruvate dehydrogenase,
indicative of mitochondrial TCA cycle activity in both cell lines.
However, the synthesis rate of 4-13C-glutamate was two-fold higher in
4T1 cells than in 67NR cells at 6 to 11 hours of perfusion with
1-13C-glucose in the perfusate (Figure 1C). To further investigate the
TCA cycle activity and metabolite contributions to anaplerosis [29], we
considered a dynamic flux analysis based on the time-course changes of
the different 13C-glutamate isotopomers (Figure 3, A and B). This
model estimated a 2.2 ± 0.6-fold higher TCA cycle flux [F(tca)] in 4T1
cells than in 67NR cells (Figure 3C), which is consistent with the
differences in OCR measurements (Figure 2, B and C). The TCA flux
analysis model projected identical relative exchange fluxes between
α-ketoglutarate and glutamate in both cell lines [F(x)/F(tca), Figure 3C].
However, the total exchange estimated at the levels of succinyl-CoA,
fumarate, and oxaloacetate (OAA), i.e., anaplerotic/cataplerotic fluxes
[F(ana)], was 3.2 ± 0.8-fold higher in 67NR cells than in 4T1 cells,
although not significantly. Moreover, the estimated pyruvate carbox-
ylase flux F(pc) (OAA–pyruvate exchange) was significantly higher in
67NR cells than in 4T1 cells (Figure 3C). Accordingly, the time-course
changes in the 2-13C/4-13C glutamate ratio (bb1, Figure 3D) suggest
that pyruvate is channeled to the TCA cycle mostly via pyruvate
dehydrogenase [30] in both cell lines, whereas the changes in 2-
13C-glutamate to 3-13C-glutamate ratio (Figure 3D) reflect differences
in pyruvate carboxylase activity according to glutamine availability. In
the presence of 2 mM glutamine (Figure 3D, 1-6 hours), both cell lines
displayed similar 2-13C-glutamate to 3-13C-glutamate ratios (~1.5-2),
suggesting similar pyruvate carboxylase activity. However, after
increasing glutamine to 6 mM (Figure 3D, 6-11 hours), the 2-
Figure 2. Mitochondrial respiration of breast cancer cells with different metastatic potential. Extracellular flux analyzer experiments
(Seahorse Bioscience XF96) for different cell lines using XF assay medium containing 25 mM glucose and 6 mM glutamine: 4T1 and
67NR: n=4 (A–C); 4T1, 4T07, 168FARN, and 67NR: n= 1 (D–E). (A) The logarithm of ratios of ECARs (mpH · min−1 · mg protein−1) of 4T1
and 67NR cells, ECAR(4T1)/ECAR(67NR), plotted repeatedly over 27 minutes. (B) OCR (pMol · min
−1 · mg protein−1) measurements for 4T1
and 67NR cells, respectively. (C) For 4T1 and 67NR cells, the following mitochondrial respiration parameters were calculated from the
OCR curves shown in B: nonmitochondrial respiration, proton leak, basal respiration, ATP production, maximal respiration, and spare
respiratory capacity. An additional experiment, performed as described for B and C, included four isogenic cell lines and is shown in D and
E, respectively. In A, * indicates significant differences between 4T1 and 67NR cells at successive time points (P = .021, .023, .041, and
.05, respectively) and for the geometric mean across time points (P = .034) based on one-sample t tests of the log-ratios across
experimental replicates.
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changed in 67NR cells but significantly decreased in 4T1 cells (~1),
suggesting a reduction in pyruvate carboxylase activity, likely due to
more glutamine availability to replenish the TCA cycle at the level of
OAA. Altogether, our results indicate a rate-limiting step of the TCA
cycle downstream ofα-ketoglutarate in 67NR cells. This is summarized
in our proposed model (Figure 4, A and B).TCA Cycle Restriction in 67NR Cells
The nonmetastatic 67NR cells showed a strong accumulation of
1-13C-glucose–derived succinate (2-13C-Succ) under full nutrient
conditions, whereas glucose-derived succinate was essentially not
detected in 4T1 cells (Figure 1, A–C). High-resolution MR analysis
of TCM samples collected at the end of each experimental stage
(Supplementary Experimental Procedures) also showed that 67NR
Figure 3. TCA cycle flux analysis of 4T1 and 67NR cells. Representative examples of flux fitting for 4T1 (A) and 67NR (B) cells during the 6-
to 32-hour perfusion period with 99% 1-13C-Glc and 6 mM glutamine based on the time courses of labeled glutamate isotopomers C4
(E4glu), C3 (E3glu), and C2 (E2glu), and the estimated glutamate C4 singlet (Glu4s, 98%) and doublet (after one turn of the TCA cycle:
Glu4d34, 2%). The solid lines are the fits of the kinetic model to the data. Dashed lines are the predicted Glu4d34 from themodel. (C) From
left to right: estimations of TCA cycle flux [F(tca)], α-ketoglutarate to glutamate flux [F(x)] relative to F(tca), anaplerotic flux [F(ana), total
exchange estimated at the levels of succinyl-CoA, fumarate, and OAA; center panel] relative to F(tca), and pyruvate carboxylase flux [F(pc)
relative to F(tca)]. (D) Experimental time-course data for 4T1 and 67NR cells illustrate the relative fluxes estimated by the model (shown in
C) in presence of 2 mM glutamine (1-6 hours) and 6 mM glutamine (6-32 hours): left panel, Glu C2/C4 ratios; right panel, Glu C2/C3 ratios.
Significantly higher Glu C2/C4 and Glu C2/C3 ratios in 67NR than 4T1 cells, indicative of a higher F(pc)/F(tca) and F(ana)/F(tca), respectively.
Neoplasia Vol. 17, No. 8, 2015 Metabolic Determinants of Metastatic Breast Cancer Simões et al. 677cells extruded 5.8-times more succinate than 4T1 cells (data not
shown). The accumulation of glucose-derived succinate observed in
67NR cells was further investigated by perfusing each cell line with
3-13C-glutamine during regular growth conditions (1-6 hours),
under reversible hypoxia (6-11 and 16-21 hours), and under glucose
starvation (11-21 hours) (Table 1, Study B). The time-course changes
in phospholipid metabolism, bioenergetic profiles, pHi, or pHe
essentially showed the same trends in both cell lines under glucose
deprivation or hypoxia (Figure S4).
3-13C-glutamine–derived succinate levels (2-13C-Succ) were always
significantly higher in 67NR cells than in 4T1 cells in the cell perfusion
system for all the microenvironment conditions (Study B, Table 1)
tested (Figure 5A). 67NR cells synthesized 2-13C-succinate under
aerobic conditions, either from 1-13C-glucose (Figure 1, A–C) or from
3-13C-glutamine (Figure 5, A and B; 1-6 and 11-16 hours). The
accumulation of 2-13C- succinate from 3-13C-glutamine in 4T1 cells
could only be detected during hypoxia with glucose-containing
perfusate (Figure 5, A and B; 6-11 hours). This is consistent with a
reductive turnover of the TCA cycle, as recently shown in other cancer
cell lines growing in hypoxia [31] or with defective mitochondria [32].
In 4T1 cells (and not in 67NR cells), 13C-labeled aspartate (2-13C and
3-13C, in equilibrium with OAA labeled in the same positions) was
detected only when oxygen was available (Figure 5A, 1-6 and 11-16
hours) and not under hypoxia (Figure 5A, 6-11 and 16-21 hours).
Full glucose deprivation under well-oxygenated conditions
caused a slight (not statistically significant) increase in the levels of
3-13C-glutamine–derived aspartate in 4T1 cells and of succinate in67NR cells (Figure 5A, 1-6 vs. 11-16 hours), with no corresponding
differences between the rates of synthesis (Figure 5B). These findings
indicate that the glucose concentration does not have a significant
effect on the oxidation of glutamine through the TCA cycle in both
cell lines. This backs up a prior observation in a human lymphoma
cell line that supports the existence of an alternative carbon source
pathway into the TCA cycle driven by glutamine and independent of
glucose [33]. Our results, together with the flux model predictions
based on glutamate isotopomer analysis (Figure 3), suggest that the
lower TCA cycle activity observed in 67NR cells is due to a restriction
in TCA cycle flux at the level of SDH (respiratory complex II)
(Figure 4).
SDH-A Protein Expression Pursuant to Metastatic Ability and
Cell Line-dependent Response to Environmental Stresses
We investigated if the lower TCA cycle activity in 67NR cells and
the accumulation of succinate could be explained by a deficiency in
SDH expression and/or activity. Western blots showed a significant
four-fold lower expression of SDH-A (FAD-containing subunit that
binds succinate) in 67NR cells than 4T1 cells (Figure 6A). The
enzyme activity of SDH was also significantly lower (six-fold) in
67NR cells than in 4T1 cells (Figure 6B). Because an impairment of
SDH should directly affect mitochondrial respiration, these results are
consistent with the approximately two-fold higher basal respiration
rate and ATP production observed in 4T1 cells compared with 67NR
cells (Figure 2C). The expression of SDH-A in regular medium
conditions (25 mM Glc, 6 mM Gln) was noted to increase with
Figure 4.Metabolicmodel for 4T1 and 67NR cells. (A) Extracellular 1-13C-Glc (carbonsC1-6 shown as spheres; 13C-labeled carbon in black) in
themedium is takenupby thecells viaGLUT transporters. Glucose is thenmetabolized through theglycolytic pathway, labeling 50%of thede
novo pools of myo-inositol (C2, C4), DHAP (C1), and glycerol-3-phosphate (C1), which could be detected in the cell perfusion system
experiments (Figure 1). Pyruvate (C3 labeling) can be further metabolized in the cytosol to lactate (C3 labeling), regenerating the NAD+
consumedduringglycolysis, or to alanine (C3 labeling) by transaminationof glutamatewithpyruvate. Alternatively, pyruvate canbechanneled
to the mitochondria and converted to acetyl-CoA (C2 labeling) via pyruvate dehydrogenase (PDH). Acetyl-CoA enters the TCA cycle and
condenses with OAA (initial unlabeled pool) to produce citrate, which then transfers its label to α-ketoglutarate (C4). The exchange between
α-ketoglutarate (fast turnover) and glutamate (C4 labeling) makes the latter a marker of TCA cycle activity. The C4 label of α-ketoglutarate is
then transferred to succinateC2 (or C3; not distinguishable) and then toOAAC2 (C3). Because succinateC2 (C3) accumulates in 67NRcells, it
is likely that their TCA cycle is restricted at the level of SDH, leading to lower flux to OAA (green arrows; higher flux expected in 4T1 cells,
displayed by red arrows). After this first turn of the TCA cycle, a significant part of the intermediates has been removed for biosynthetic
purposes; the remainingOAAcanbeused for the second turn— reactions indicated by the dottedgray arrowsand the resultingmoleculesby
the gray spheres (13C label, gray; unlabeled, white). In this case, the resulting labeling pattern of glutamate ismore complex and generates an
additional 1:1 pool of C2 and C3 labeling (highlighted by short gray arrows). (B) Besides PDH, an alternative way for pyruvate to enter the TCA
cycle is through pyruvate carboxylase (PC). This anaplerotic pathway becomesmore important when glutamine is not sufficiently available to
cells or they cannot use it to regenerate OAA. In this case, the first turn of the TCA cycle will generate a 1:1 labeling of glutamate in positions
C4 and C2 (indicated by short gray arrows).
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hypoxic cells (Table 2). Hypoxia itself affected SDH-A expression
depending on the metastatic potential (Table 2, Figure 6C):
downregulation in 67NR (nonmetastatic), upregulation in 4T1
(metastatic) (P = .003), and intermediate effects in the other two cell
lines characterized by local micrometastases. Relative to 4T1 cells,
glutamine deprivation (0 mM and 2 mM Gln) lowered SDH-A
protein expression in the three less metastatic cell lines more than
glucose deprivation (Table 2). These results suggest a better ability of
4T1 cells to use the TCA cycle, even under stress, than the other three
cell lines.
Metabolic Adaption to Nutrient (Glucose, Glutamine) Sup-
plyin 4T1 than in 67NR Cells
To further understand the metabolic differences between 4T1 and
67NR cells, we investigated the effects of glucose and glutamine
deprivation on glucose metabolism. Using standard 2D tissue culture
conditions (Figure S5), we found that the cell growth significantly
decreased by approximately five-fold in both cell lines when they were
fully deprived of either glutamine or glucose. In response to partial
glutamine deprivation (2 mM), an approximately two-fold decreasewas observed in both cell lines. Therefore, both 4T1 and 67NR cells
depend on glucose and glutamine to grow.
For the cell perfusion experiments performed under cellular stress
conditions (Table 1, Study C), we selected 2 mM glutamine over 6
mM to more closely simulate the glutamine levels observed in vivo
(~0.5 mM Gln, [34,35]). Under aerobic conditions, metastatic 4T1
cells perfused with medium containing 2 mM glutamine (Figure 1, B
and C; 1-6 hours) responded to full glutamine deprivation by
significantly reducing their glycolytic lactate synthesis (2.3-fold) to
levels similar to those observed in 67NR cells under the same
conditions (Figure 7, A and B; 1-6 hours). In comparison, the 67NR
cells did not significantly alter their lactate synthesis rate with
glutamine deprivation under comparable conditions. This differential
response to glutamine deprivation is likely related to its importance as
a major anaplerotic precursor of the TCA cycle together with higher
TCA cycle function in 4T1 cells compared with 67NR cells.
Based on our experimental data and our proposed metabolic
model (Figure 4), glutamine deprivation would have a higher impact
in replenishing the OAA pool in 4T1 cells than in 67NR cells. As a
result, glutamine-deprived 4T1 cells would become more
dependent on glucose-derived carbon (pyruvate) entering the TCA
Figure 5. Cell perfusion stress studies with 3-13C-glutamine. Normalized average time-course changes of metabolite levels (A) and
13C-labeling rates at different time intervals (B) for succinate C2, aspartate C2, and aspartate C3 determined from 13C MR spectra under
environmental conditions as detailed in Table 1 (Study B).
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basal metabolic phenotype of 67NR cells. A corresponding reduction
of the synthesis rate of lactate would be expected, as we observed
(Figure 7, A and B). However, full glutamine deprivation underFigure 6. SDH expression and activity in breast cancer cells with di
higher in 4T1 than 67NR cells, as shown in a representativeWestern b
SDH-A/β-actin ratios over three independent experiments (right, b
spectroscopy at 600 nm in 4T1 and 67NR cells (dots are average valu
each cell line (slope = SDH activity): 4T1, 1.97 ± 0.28 (R2 = 0.98);
expression in hypoxia to normoxia for 4T1, 4T07, 168FARN, and 67N
6 mM Gln.aerobic conditions reduced TCA cycle flux ~2.3-fold in both cell
lines, as evidenced by the significant decrease of glucose-derived
glutamate (Figure 7, A and B; 1-6 hours, 0 mM Gln). Our results
show that the synthesis rate of glucose-derived lactate is higher infferent metastatic potential. (A) Protein expression of SDH-A was
lot of 4T1 and 67NR cells (left panel) and quantified by averaging the
ar graph). (B) SDH activity assessed kinetically by absorbance
es of at least three independent experiments) and linear fittings for
67NR, 0.32 ± 0.03 (R2 = 0.99). (C) Ratio of cellular SDH-A/β-actin
R cell lines exposed to culture medium containing 25 mM Glc and
Table 2. SDH-A Expression in Four Isogenic Breast Cancer Cell Lines under Environmental Stress
Medium Cell Lines
Glc Gln 67NR 168FARN 4T07 4T1
(mM) (mM) (Ox) (H) (Ox) (H) (Ox) (H) (Ox) (H)
0 6 0 +1 +3 +2 −1 −2 (ref) +2
25 6 −1 −2 0 0 −1 +1 (ref) +2
25 2 −3 −3 −2 −3 −3 −3 (ref) 0
25 0 −2 −3 −2 0 −2 −2 (ref) −1
For each independent experiment (n = 3), SDH-A expression levels assessed by Western blot were
normalized to β-actin and ranked separately for each condition [glucose and glutamine
concentrations and effect of hypoxia (H)] with respect to expression levels of well-oxygenated
(Ox) 4T1 cells. Legend: +3 N150%; +2 N125%; +1 N110%; 0 ±10%; −1 b90%; −2 b75%; −3
b50%.
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0.47) and more dependent on glutamine in the former (Km = 0.63 ±
0.01) than in the latter (Km = 0.16 ± 0.03) cells. Thus, the
aerobic synthesis rate of lactate from glucose [Vm(4T1/67NR) ~1.6]
requires approximately a four-times higher glutamine concentration
in the medium for metastatic 4T1 cells than for nonmetastatic
67NR cells [Km(4T1/67NR) ~4] (Figure 7C). This effect is also
apparent for the entire panel of isogenic cell lines in 2D cell culture
(Figure 8A), as increased glucose-derived lactate synthesis rates were
associated with higher metastatic ability and stronger dependency on
glutamine levels.
Interchangeability of Glycolysis and OXPHOS in 4T1 cells
When 4T1 and 67NR cells are fully deprived of glutamine and
subsequently exposed to hypoxia, the glycolytic lactate synthesis rate
increased by ~1.8-fold in both cell lines (Figure 7, A and B; 6-11
hours), although this increase was significant only in 67NR cells. This
observation is expected because 1) hypoxia is a driver of increased
glucose uptake and glycolysis [36] and 2) less glucose is being
consumed by the TCA cycle under hypoxic conditions, as shown by
the low levels of de novo glutamate synthesis (Figure 7, A and B; 6-11
hours). After replenishing glutamine-starved, hypoxic 4T1 cells with
glutamine (2 mM), glycolytic synthesis of lactate significantly increased
1.9-fold (P = .011, paired t test), whereas it remained unchanged in 67NR
cells exposed to the same nutrient conditions (Figure 7, A and B; 11-16
hours). Although the glutamine-containing medium used in these studies
contained pyruvate (1 mM), similar changes in the synthesis rates of lactate
and glutamate were obtained for cells in pyruvate-free medium under the
same environment stress conditions studied above (results not shown).
Furthermore, MR analysis of TCM2D samples from the four isogenic cell
lines grown in hypoxia also indicates a higher lactate synthesis rate in more
metastatic cell lines with higher glutamine availability (Figure 8B).
In the last stage of the cell perfusion experiments, shown in Figure 7,
A and B, reoxygenation (16-21 hours) of the nutrient-replenished 4T1
cells significantly decreases (2.5-fold) the synthesis rate of glucose-
derived lactate, whereas no change was observed in 67NR cells. During
this period, the synthesis rate of glucose-derived glutamate was 2.4-fold
higher in 4T1 cells than in 67 NR cells, consistent with a stronger
reactivation of TCA cycle flux in 4T1 cells following the reintroduction
of oxygen and glutamine. Thus, less glucose transitioned to lactate in
4T1 cells, and de novo succinate from glucose accumulated in 67NR
cells (but not in 4T1 cells) (Figure 7, A and B). These observations
agree with the results of the initial cell perfusion experiments performed
under standard growth conditions (Figure 1).No significant differences in Pii, Pie, or pHi were detected between
4T1 and 67NR cells during the periods of full glutamine deprivation
and hypoxia (Figure S6, 1-11 hours). Whereas significant differences
in extracellular pH were detected during initial glutamine deprivation
(Figure S6, 1-6 hours), the time-course changes in both cell lines
followed the same trend. During these periods, the nonmetastatic
67NR cells consistently accumulated more PCho, decreased GPCho/
PCho ratios, and had significantly higher levels of β-NTP than 4T1
cells (Figure S6, Table S1). These results suggest that, compared with
4T1 cells, the energy metabolism of 67NR cells is less sensitive to
short-term glutamine deprivation and hypoxic stress because they rely
less on OXPHOS than 4T1 cells. The slight decrease of β-NTP levels
detected in 4T1 cells (compared with initial values; Table S1, Study
C) could also reflect an attempt of the metastatic phenotype to
maintain a high glycolytic flux by removing ATP-induced inhibition
on phosphofructokinase [37].
Discussion
We investigated the dynamic flux of glucose through glycolysis and
the TCA cycle, and the flux of glutamine through the TCA cycle.
Experiments were performed on a panel of isogenic murine cell lines
derived from the same spontaneous breast tumor, focusing mostly on the
highly metastatic (4T1) and nonmetastatic (67NR) variants [16]. We
found significant differences in metabolism between these two cell lines.
Themore aggressive cell line (4T1) had higher glycolytic, OXPHOS, and
TCA cycle activity than 67NR cells to meet their energy and anabolic
requirements for rapid proliferation and the formation of metastases. 4T1
cells adapted more readily than 67NR cells to a changing microenviron-
ment. This is accomplished by a greater ability to regulate glucose
metabolism through glycolysis and/or oxidative metabolism. This
“plasticity” of 4T1 cells is also supported by our previous experiments
[17,23]. For instance, 4T1 cells, which have higher basal levels of LDH-A
expression than 67NR cells [17], significantly increased their OCR in
response to LDH-A knockdown and reduced aerobic glycolysis [23].
Further, we identified a restriction of TCA cycle flux in 67NR cells
but not in 4T1 cells. This was found to be due to lower expression of
SDH in 67NR in comparison to 4T1 cells. Thus, 67NR cells
accumulated significantly more succinate and displayed significantly
lower OXPHOS activity than 4T1 cells under standard growth
conditions. These data agree well with the study by Lu et al. [21],
which used targeted liquid chromatography–mass spectrometry to
assess the metabolomic profile of a panel of nonmetastatic and
metastatic murine breast cancer cell lines, including 67NR and 4T1.
Under standard tissue culture conditions, they also reported higher
succinate levels in 67NR than in 4T1 cells (Table S2, [21]). The
accumulation of succinate has also been associated with a
“pseudohypoxic” cellular microenvironment that stabilizes HIF-1α
[38]. Stabilization of HIF-1α is associated with upregulation of
angiogenesis-related proteins, e.g., VEGF [39]. This would agree with
our previous observations [17] and others [40], demonstrating that 1)
67NR tumors have better vascular perfusion than 4T1 tumors at
comparable tumor sizes and 2) 67NR cells are better adapted to
growing in hypoxia [17]. Although SDH has been proposed as a
tumor suppressor gene [38], no evidence of its epigenetic silencing has
been found in clinical breast cancers [41]. Thus, the presence of a
fully functional TCA cycle (including SDH and OXPHOS) may be a
hallmark of metastatic breast cancer.
Our results suggest lower SDH-A expression in less aggressive cell
lines either in replete environmental conditions or under stress
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Kim et al. showing an association between low SDH expression and
low-grade histology in a panel of 721 breast cancers [42]. With
relatively less efficient mitochondrial OXPHOS activity, less
aggressive cell lines could potentially reduce their TCA cycle by
channeling glucose into other, more efficient pathways. This would
also agree with data from our group indicating upregulation of
phosphoenolpyruvate carboxykinase (PCK1) aligning with decreased
metastatic ability (67NR N 168FAR N 4T07NN 4T1, Figure S7).
Together with our estimates of relatively lower pyruvate carboxylase
flux in 4T1 cells, this would suggest lower gluconeogenic potential in
more aggressive breast cancer phenotypes, in agreement with the loss
of fructose-1,6-bisphosphatase in basal-like breast cancer [43].
Moreover, higher relative levels of SDH-A in hypoxic 4T1 cells
could be a response to the increased levels of glutamine-derived
succinate (reductive carboxylation pathway [44]), whereas SDH-A
decreases in hypoxic 67NR cells. Therefore, although more adaptable
to changes in their microenvironment, more aggressive cell lines may
preserve a relatively higher basal potential for aerobic metabolism
under stress, enabling faster adaptation to new microenvironments.Figure 7. Cell perfusion stress studies with 1-13C-glucose as detaile
(A) and labeling rates at different time intervals (B) of lactate C3, glutam
the rates in the gray boxes are from the experiments shown in Figure 1
experiments C-2, A-2, and A-3 (detailed in Table 1) and displayed in A (
hours, 6 mM Gln) were fitted according to the Michaelis-Menten asy
(data not shown), when changing from 6 mM to 0 mM glutamine-con
was estimated in the cell microenvironment at the beginning of theAs summarized in Table S2, recent data support an association
between mitochondrial function and metastatic potential in breast
cancer, and an association with a short metastasis-free survival [45].
The ability to effectively use OXPHOS in addition to glycolysis has
been demonstrated in aggressive breast cancer cell lines [46–48] and
proposed as a key adaptation for developing brain metastasis [19]. A
recent model of tumor metabolism also suggested that stromal cells
fuel breast cancer cell growth and the development of metastasis
through mitochondrial metabolism [20]. Lu et al. showed that TCA
cycle intermediates increase with metastatic potency in isogenic
67NR, 168FARN, 4T07, and 4T1 cells [21]. In our studies with the
same panel of cell lines, we found this to be related to higher
OXPHOS, indicating that higher metastatic potential is associated
with less reliance on aerobic glycolysis alone. The higher utilization
of OXPHOS in primary 4T1 tumors may contribute to the
development of necrosis due to outgrow of their vascular oxygen
supply [17]. Our previous attempts to inhibit 4T1 cancer growth and
metastasis focused on LDH-A knockdown alone [23]. These new
observations suggest that mitochondrial metabolism (OXPHOS)
is also a potential target for treatment in this breast cancer model.d in Table 1 (Study C). Normalized average time-course changes
ate C4, and succinate C2 as determined from 13CMR spectra. In B,
C and displayed again for comparison. (C) The values obtained from
1-6 hours, 0 mM Gln) and Figure 1C (1-6 hours, 2 mM Gln; and 6-11
mptotic model. Because the cellular washout of glutamine is slow
taining perfusion media, a 5% residual level of glutamine (0.3 mM)
study. Error bars indicate the standard error of the means.
Figure 8. Absolute rates of 1-13C-glucose consumption and de novo 1-13C-glucose–derived lactate synthesis in breast cancer cells of
different metastatic potential and under different stresses. Each cell line was incubated with 1-13C-glucose for 5 hours, either in 20% O2
(A) or in 1% O2 (B), and TCM2D samples were collected for high-resolution
13C-MR studies. Extracellular 1-13C-glucose consumption and
1-13C-glucose–derived lactate synthesis rates were averaged over three independent experiments for each condition. # Statistically
significant change with respect to same cell line in medium containing 6 mM Gln.
682 Metabolic Determinants of Metastatic Breast Cancer Simões et al. Neoplasia Vol. 17, No. 8, 2015Thus, combined metabolic inhibition of both the glycolytic and
OXPHOS pathways may prove to be more effective in the treatment of
metastatic breast cancer.
Glutamine is an essential nitrogen source for the synthesis of
nucleotides, amino acids, and ATP, and a major anaplerotic precursor
for the TCA cycle [27]. Glutamine addiction is frequent in cancer
cells [49] and has been linked to Myc overexpression [33]. Previous
work has shown that Myc expression is 2.3-fold higher in 4T1 than in
67NR cells [50]. Singh et al. observed in a panel of aggressive,
glutamine-addicted breast cancer cell lines (including 4T1) a
correlation between glutamine addiction and metastatic ability [51].
More recently, glutamine dependency was associated with higher
invasion and metabolic “rewiring” in ovarian cancer cell lines;
specifically, glutamine downregulated glycolysis (glucose uptake and
lactate secretion) in highly invasive cancer cells but not in cancer cells
with low invasive potential [52]. Similarly, we observed that lactate
production by aerobic glycolysis (Warburg effect) is four times more
glutamine dependent in 4T1 cells than in 67NR cells. However,
in our study, glutamine stimulated the synthesis of glucose-derived
lactate according to metastatic potential. Compared with the studies
by Yang et al. [52], this could indicate 1) basal metabolic differences
between the two cancer cell types (ovarian and breast) and/or 2)
different effects of glutamine during the metabolic reprogramming
toward more invasive or metastatic phenotypes. Because lactate is a
major driver of invasion and dissemination [14,15], our data suggest
that glutamine deprivation might prevent production of lactate and
inhibit/delay breast cancer metastases. Glutamine was found to
recycle into OAA only in 4T1 cells (as shown by the labeling of
aspartate from 3-13C-glutamine studies), whereas nonmetastatic
67NR cells are more dependent on glucose as an anaplerotic precursor
of the TCA cycle via pyruvate carboxylase. Accordingly, the flux
analysis of our cell perfusion data (in high-glutamine–containing
medium) predicted an exchange at the level of pyruvate carboxylase
only in 67NR cells and not in 4T1 cells. This also explains the
marked dependency of glycolytic lactate synthesis on glutamine
observed in 4T1 cells but not in 67NR cells. To sustain their higher
ATP demands by OXPHOS, glutamine-deprived 4T1 cells must rely
more on glucose to replenish the OAA pool of the TCA cycle (via
pyruvate carboxylase). This is accomplished by increasing the amount(fraction) of glucose used for de novo synthesis of citrate. Both cell
lines ultimately respond to full glutamine deprivation by reducing the
TCA cycle flux and decreasing their lactate synthesis rates to similar
levels. This observation agrees with the results reported by Richardson
et al. in a panel of transformed MCF-10 breast cancer cells grown in
glutamine-free medium [53], which showed no significant differences
in lactate excretion rates with increasing malignancy and metastatic
potential. Thus, limiting OXPHOS by targeting glutamine metab-
olism [28] may provide an additional therapeutic approach for
metastases-prone or metastatic breast cancer, although other
modulators of cellular adaptation should be considered, such as
asparagine [54].
Conclusions
Whereas most previous investigations have focused on identifying
gene signatures associated with the pathophysiology of metastases
[55], our results suggest that the noninvasive evaluation of a tumor’s
metabolic phenotype can provide useful information related to the
metastatic propensity of the tumor. We show that 4T1 metastatic
breast cancer is associated with metabolic plasticity in response to
changing tumor cell microenvironments. Specifically, these cells use
OXPHOS efficiently during optimal growth conditions (whereas
nonmetastatic 67NR cells do not) and reversibly shut down OXPHOS
during transient hypoxia and/or glutamine deprivation. These transitions
were dynamically quantified for the first time with tumor cell perfusion
experiments that closely mimic the in vivo tumor microenvironment. The
observedmetabolic differences and the ability to assess adaptability in living
cells provide the opportunity to identify new biomarkers for early detection
of the metastatic phenotype, possibly at the time of diagnosis. Metabolic
therapies directed at inhibiting both the glycolytic andOXPHOSpathways
are also suggested by these studies; such combination therapies may be
more effective in the treatment of aggressive metastatic breast cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.08.005.
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